This study evaluated Zonisamide Weight Loss in Obese Adults. Among 51 randomized subjects, seven percent of the responders had lost at least 10 percent of their body weight, while none of the placebo-treated groups achieved this level. At the end of the trial, a total of 5.5 kg of excess body fat had been lost, which was statistically significant compared to the placebo. In addition, zonisamide was well tolerated by participants. In addition, the drug reduced cravings for sweets.
However, Zonisamide Weight Loss in Obese Adults may not be suitable for all patients. While zonisamide inhibits carbonic anhydrase, it has also been shown to alter taste. Researchers have not confirmed this relationship between zonisamide and obesity, but this effect does have some positive impact on weight loss. This drug may be the solution to your problem of obesity. As an oral dietary supplement, Zofran is an excellent choice for people who are trying to lose weight.
With Zonisamide Weight Loss in Obese Adults study, weight loss was observed in 76% of the patients. The study participants were given hypocaloric diets for up to eight weeks after starting zonisamide treatment. Some of the side effects included nausea/vomiting, fatigue, and gastrointestinal problems. Nonetheless, overall weight loss was observed in all groups. Although the treatment is not yet approved for treating severe underlying conditions, zonisamide is a viable option for patients with weight-loss concerns.
With Zonisamide Weight Loss in Obese Adults study, participants took either 200 mg or 400 mg of zonisamide daily for eight weeks. The study results showed that zonisamide did indeed reduce body weight, and the results were consistent with the expected outcomes. In addition, the weight change was higher in the full-dose compliant group. In addition, further analysis showed that zonisamide induced more weight loss than the placebo.